European Commission opens proceedings against Lundbeck

Published: 7-Jan-2010

Danish pharmaceutical company Lundbeck is cooperating with the European Commission in its formal investigations into allegations of unfair business practices relating to the anti-depressant drug citalopram.


Danish pharmaceutical company Lundbeck is cooperating with the European Commission in its formal investigations into allegations of unfair business practices relating to the anti-depressant drug citalopram.

The Commission suspects the company of using its dominant market position to hinder sales of citalopram, a selective serotonin reuptake inhibitor (SSRI), or has been involved in anticompetitive agreements in the markets for the drug.

Lundbeck said it was cooperating fully with the European Commission and was confident that it has complied with all relevant national and EU competition legislation.

The European Commission said the opening of proceedings did not mean that it had proof of the infringements but merely that it would investigate the case as a matter of priority.

Lundbeck, based in Copenhagen, is an international pharmaceutical company focused on improving the quality of life for people suffering from central nervous system (CNS) disorders, such as depression, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's diseases.

See more

You may also like

Media

Domain Therapeutics receives $125m to assign its intellectual property

Read more
Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Media

Domain Therapeutics receives $125m to assign its intellectual property

Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Moving to continuous processes

As both the regulators and equipment manufacturers push the concept of continuous manufacturing, the mindset is filtering down from research and API production to finished products. But are all the requirements in place to make it successful? Susan Birks reports
Finance

Lundbeck embarks on another restructuring to drive profit and ensure growth

Will cut around 1,000 jobs in Europe
Media

Alzheimer’s treatment market value to exceed US$13bn by 2023

Rising prevalence, advances in diagnostic capability and greater awareness will drive growth
Finance

Lundbeck to buy Chelsea Therapeutics for US$658m

Danish company gains rights to FDA-approved Northera for the treatment of neurological disorders
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Finance

New products drive growth at Lundbeck in 2013

Received five approvals from US and European regulators
Subscribe now